Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
Swedish Orphan Biovitrum AB (Sobi) announced that the FDA has granted Fast Track designation to pacritinib, a dual IRAK1/JAK2 inhibitor, for treating VEXAS syndrome. The designation accelerates development and review of the drug, which is currently in Phase II trials. Topline data from the PAXIS study is expected in 2027. VEXAS syndrome is a rare, debilitating systemic disorder with no currently approved treatments.